Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication

Table 3 Adverse events and compliance n (%)

	MBST	Hybrid	P value
Adverse events	(n = 136)	(n = 138)
Bloating/dyspepsia	4 (2.9)	5 (3.6)
Taste distortion	4 (2.9)	4 (2.9)
Epigastric discomfort	4 (2.9)	7 (5.1)
Nausea	2 (1.5)	4 (2.9)
Abdominal pain	0 (0.0)	0 (0.0)
Diarrhea	2 (1.5)	7 (5.1)
Total	16 (11.8)	27 (19.6)	0.019
Compliance	136 (100.0)	138 (100.0)

MBST: 14-d moxifloxacin-based sequential therapy; Hybrid: 14-d hybrid therapy.